China Biotech/Pharma Sector: 1H26 Results Wrap and Pipeline Catalyst Table
We track 36 major commercial-stage biotech/pharma companies in China for key takeaways/readthroughs and updated sector's major pipeline catalysts...
112 Views
Quiddity Leaderboard HSCEI Jun26: Two ADDs/DELs Likely but One Name Close to Escaping Deletion
We see one high-conviction ADD/DEL and one low-conviction ADD/DEL. Since the reference period is not over yet, our expectations can still change.
322 Views
BUY/SELL/HOLD: Hong Kong Market Update (August 2026)
The Hong Kong market continues to show gains on the back of a strong July. The standout sectors this month include materials and healthcare.
104 Views
APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion
Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....
100 Views
Hansoh Pharma (3692 HK): Yet Another Out Licensing Agreement Underpins Hansoh’s Pipeline Strength
Hansoh Pharma granted Glemark license for aumolertinib, a third-generation EGFR-TKI drug with multiple indications approved in China and UK....
498 Views